Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - jamanetwork.com
Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …
被引用次数：45 相关文章
[HTML] nih.gov

[HTML][HTML] Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - ncbi.nlm.nih.gov
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in
Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma …

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - pubmed.ncbi.nlm.nih.gov
Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …
[PDF] researchgate.net

[PDF][PDF] Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA, 2022 - researchgate.net
OBJECTIVE To investigate the efficacy of trastuzumab and PD-1 inhibitors with cytotoxic T-
lymphocyte–associated antigen 4 (CTLA-4) inhibitors or FOLFOX in first-line treatment of …

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - europepmc.org
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in
Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The …

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric …

A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - europepmc.org
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in
Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The …